Article
Potentiation of inhibition of wild-type and mutant human immunodeficiency virus type 1 reverse transcriptases by combinations of nonnucleoside inhibitors and d- and L-(beta)-dideoxynucleoside triphosphate analogs.
Antimicrobial agents and chemotherapy - 1 Apr 2001
Maga G, Hübscher U, Pregnolato M, Ubiali D, Gosselin G, Spadari S
Abstract excerpt
Combinations of reverse transcriptase (RT) inhibitors are currently used in anti-human immunodeficiency virus therapy in order to prevent or delay the emergence of resistant virus and to improve the efficacy against viral enzymes carrying resistance mutations. Drug-drug interactions can result in either positive (additive or synergistic inhibition) or adverse (antagonistic interaction, synergistic toxicity)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
